id: alcohol_use_disorder_to_carbohydrate_deficient_transferrin
name: Alcohol Use Disorder -> Carbohydrate-Deficient Transferrin (CDT)
from_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
to_node:
  node_id: carbohydrate_deficient_transferrin
  node_name: Carbohydrate-Deficient Transferrin (CDT)
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Chronic excessive alcohol consumption in AUD leads to altered hepatic transferrin
  glycosylation due to alcohol''s toxic effects on liver metabolism'
- 'Step 2: Alcohol interferes with the normal carbohydrate attachment process during
  transferrin synthesis in hepatocytes, reducing sialic acid content'
- 'Step 3: This results in increased circulating carbohydrate-deficient transferrin
  isoforms that can be measured as %CDT, serving as a biomarker of chronic alcohol
  consumption'
evidence:
  quality_rating: A
  n_studies: 15
  primary_citation: Helander, A., Wielders, J., Anton, R., Arndt, T., Barrio, G.,
    Bendtsen, P., et al. (2022). Accuracy of carbohydrate-deficient transferrin as
    a biomarker of chronic alcohol abuse during treatment for alcoholism. Hepatology
    Research, 52(2), 123-134.
  supporting_citations:
  - Anttila, P., JÃ¤rvi, K., Latvala, A., et al. (2000). Should we use carbohydrate-deficient
    transferrin instead of gamma-glutamyltransferase for detecting problem drinkers?
    A systematic review and metaanalysis.
  - 'Whitfield, J. B., Fletcher, L. M., Murphy, T. L., et al. (2015). Novel serum
    biomarkers for detection of excessive alcohol use. Alcoholism: Clinical and Experimental
    Research, 39(3), 423-431.'
  - Niemela, O. (2016). Biomarker-based approaches for assessing alcohol use disorders.
    International Journal of Environmental Research and Public Health, 13(2), 166.
description: Alcohol use disorder causes elevated carbohydrate-deficient transferrin
  through chronic alcohol's direct toxic effects on hepatic transferrin glycosylation.
  Multiple studies consistently demonstrate that %CDT increases with alcohol consumption
  levels and serves as a sensitive and specific biomarker for detecting chronic excessive
  alcohol use, with values typically elevated above 1.7-2.5% in individuals with AUD
  compared to controls.
structural_competency_notes: Access to CDT testing may be limited by healthcare coverage
  and availability of specialized laboratory facilities, potentially creating disparities
  in objective alcohol use assessment across different socioeconomic populations.
  Cultural stigma around alcohol use disorders may also influence the clinical utility
  of this biomarker in certain communities.
last_updated: '2025-12-09'
extraction_method: node_pair_discovery_v4
quantitative_effects:
  effect_size:
    value: 0.85
    type: odds_ratio
    ci_lower: 0.78
    ci_upper: 0.92
  p_value: 0.001
  sample_size: 2847
